Session » 5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

Date: Tuesday, November 12, 2019

Time: 4:30PM-6:00PM

Meeting: 2019 ACR/ARP Annual Meeting

Abstract Number: 2840

Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy

Abstract Number: 2841

A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis

Abstract Number: 2842

Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control

Abstract Number: 2843

Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects

Abstract Number: 2844

Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease

Abstract Number: 2845

Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SSI) and Visual Analogue Scale)

« View all sessions from this meeting